Two New Retinoids for Psoriasis
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Two New Retinoids for Psoriasis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1013
Article Code: 1013b
Date: November 7, 1997
Volume: 39
Pages: 105-106
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1013
Article Code: 1013b
Date: November 7, 1997
Volume: 39
Pages: 105-106
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)